Akagera announces positive Phase I data of AKG-100 in tuberculosis
AKG-100 was well tolerated at all dose levels tested, up to a maximum of 850mg.
News
Bayer and Henry Ford Health partner to boost clinical trial access
First patients dosed in Grifols Phase III immunoglobulin trials
Kairos Pharma announces interim Phase I data for ENV-105 in NSCLC
Sound Pharmaceuticals concludes subject enrolment for SPI-1005 trial
First participant dosed in Ionis’ Phase I-II ASCEND study
Novo Nordisk reports Phase III FRONTIER4 study results for denecimig
FDA clears Quoin Pharmaceuticals’ QRX003 IND for Phase II PSS trial
